The global market for cardiac surgery and heart valve devices includes tissue heart valves, mechanical heart valves, annuloplasty repair devices, transcatheter mitral valve repair (TMVr) devices, transcatheter aortic heart valve implantation (TAVI) devices, on-pump coronary artery bypass (ONCAB) devices, off-pump coronary artery bypass (OPCAB) devices, autotransfusion (AD) devices, endoscopic vessel harvesting (EVH) devices, anastomosis assist devices (AADs), ventricular assist devices (VADs), intra-aortic balloon pump (IABP) devices, patent foramen ovale (PFO) devices, atrial and ventricular septal defect (ASD and VSD) devices, left atrial appendage closure (LAA) devices, preshaped guidewires and cerebral embolic protection devices.

Globally, over 6 million cardiac surgery procedures were performed in 2020. The majority of these procedures were autotransfusion procedures followed by surgical heart valve procedures. Over the forecast period, all of the procedures included in this report are projected to experience growth, some faster than others, following COVID-19 headwinds. 

Overall, the U.S. cardiac surgery market was valued at $8.4 billion in 2022. This is expected to increase over the forecast period at a CAGR of 6.1% to reach $12.7 billion. Currently, the U.S. cardiac surgery market is dominated by Edwards Lifesciences, Abbott, and Medtronic. Throughout this medical market research, we analyzed over 30 cardiac

In 2020, the European cardiac surgery device market size was valued at €2.6 billion, with over 50,000 Transcatheter Aortic Valve Implantation (TAVI) procedures performed. Despite COVID19, the market size is expected to reach an insane €5.6 billion in 2026. Throughout this medical market research, we analyzed 40 cardiac surgery companies across 15 countries in Europe